Analysts' Top 5 Price Targets of May 5, 2025
Reading Time: 3 minutes
Liquidia Technologies [US53635D2027]: Scotiabank reaffirms Buy rating and raises the price target from $34 to $36 (130% upside potential) A US federal judge has dismissed the counterclaim from United Therapeutics against Liquidia and the FDA, allowing Liquidia's lung disease medication Yutrepia to hit the market this month. The decision means that the drug can receive final approval and be launched when United's exclusivity for the dry powder inhalation version Tyvaso expires on May 23, according to Bloomberg. Scotiabank referred to the ruling...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
